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Abstract
Background: The p53 tumor suppressor protein is mainly regulated by alterations in the half-life of the protein,
resulting in significant differences in p53 protein levels in cells. The major regulator of this process is Mdm2, which
ubiquitinates p53 and targets it for proteasomal degradation. This process can be enhanced or reduced by proteins
that associate with p53 or Mdm2 and several proteins have been identified with such an activity. Furthermore,
additional ubiquitin ligases for p53 have been identified in recent years. Nevertheless, our understanding of how
p53 abundance and Mdm2 activity are regulated remains incomplete. Here we describe a cell culture based
overexpression screen to identify evolutionarily conserved regulators of the p53/Mdm2 circuit. The results from this
large-scale screening method will contribute to a better understanding of the regulation of these important
proteins.
Methods: Expression screening was based on co-transfection of H1299 cells with pools of cDNA’s from a Medaka
library together with p53, Mdm2 and, as internal control, Ror2. After cell lysis, SDS-PAGE/WB analysis was used to
detect alterations in these proteins.
Results: More than one hundred hits that altered the abundance of either p53, Mdm2, or both were identified in
the primary screen. Subscreening of the library pools that were identified in the primary screen identified several
potential novel regulators of p53 and/or Mdm2. We also tested whether the human orthologues of the Medaka
genes regulate p53 and/or Mdm2 abundance. All human orthologues regulated p53 and/or Mdm2 abundance in
the same manner as the proteins from Medaka, which underscores the suitability of this screening methodology for
the identification of new modifiers of p53 and Mdm2.
Conclusions: Despite enormous efforts in the last two decades, many unknown regulators for p53 and Mdm2
abundance are predicted to exist. This cross-species approach to identify evolutionarily conserved regulators
demonstrates that our Medaka unigene cDNA library represents a powerful tool to screen for these novel regulators
of the p53/Mdm2 pathway.
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Background
The p53 protein is an important tumor suppressor pro-
tein and is mutated in about 50 % of human cancers [1].
Mice with a genetic disruption of the p53 gene develop
tumors at a particularly young age [2]. One of the major
functions of p53 is to control cell proliferation through
cell cycle arrest and apoptosis under conditions where
there is an increased risk of mutagenesis, for example
after DNA damage or nucleotide depletion [3]. For its
anti-proliferative activity, p53 uses two distinct cellular
pathways. As a transcription factor, p53 enhances the ex-
pression of pro-apoptotic target genes and represses
transcription of anti-apoptotic target genes [4]. In
addition, it associates with pro- and anti-apoptotic pro-
teins in the cytoplasm and controls their function [5].
Under normal growth conditions, p53 is rapidly
degraded by the 26S proteasome machinery [6]. This
process is mainly controlled by the E3 ubiquitin ligase
Mdm2 which mediates polyubiquitination of p53 and
promotes the association of p53 with the proteasome
[6, 7]. Other E3 ubiquitin ligases have been described
to substitute for Mdm2 under particular conditions
(reviewed in: [6]). The mdm2 gene is itself a tran-
scriptional target of p53, thus forming a regulatory
feed-back loop with p53. Other proteins like p14ARF,
the ribosomal protein L11, the FK605-binding protein
25 or KAP1/TRIM28 can impinge on this feedback
loop and modulate Mdm2 activity (reviewed in: [6]).
Under conditions of an increased risk of carcinogenesis,
this feedback loop is interrupted and the normally short
half-life of the p53 protein is considerably extended. This
results in a strong accumulation of p53, which, together
with post-translational modifications that activate p53,
leads to cell cycle arrest or apoptosis ([reviewed in: [6]).
Since p53 induces cell death after its activation, signifi-
cant research efforts are focused on harnessing this ac-
tivity for tumor therapy, at least for those tumors with
wild type p53. This approach, however, requires a more
detailed understanding of the regulation of p53.
In order to increase our understanding of the regula-
tion of p53 we searched for novel, evolutionary con-
served regulators of p53 and Mdm2 abundance by
performing a mammalian cell-based overexpression
screen using a cDNA library obtained from the teleost
Medaka. In order to facilitate the initial screening
process, pools of twenty-four cDNA clones from the
master library were prepared as transfection-ready plas-
mid DNA mixtures. More than one hundred hits were
identified in the first round of screening (primary
screen) using these cDNA library pools. We sub-
screened several of these hits and were able to success-
fully identify a number of proteins that were not previ-
ously known to regulate p53 and/or Mdm2 abundance.
The human homologues of several of these genes were
shown to regulate p53 and Mdm2 abundance in the
same way as the Medaka genes, demonstrating that the
identified genes are indeed regulators of p53 and/or
Mdm2 abundance.
Results
In order to find novel regulators of p53 and Mdm2, we
screened a cDNA library from the teleost Medaka. The
library was prepared from stage eighteen (neurula), stage
twenty-four (beginning of neurogenesis) and stage
thirty-two (completion of organogenesis) Medaka em-
bryos [8]. It contains almost eighteen thousand full
lengths genes of which almost fourteen thousand are an-
notated. In addition, about three thousand five hundred
full length cDNA clones with only partial sequence in-
formation are contained in the library. During library
preparation, only the most complete representative of
each gene was selected, resulting in a unigene cDNA li-
brary. In order to simplify the screening procedure,
which involved labor-intensive SDS-PAGE and Western
Blot analysis of cellular lysates, pools of twenty-four
clones were prepared as transfection ready plasmid
DNA samples. Over seven hundred such cDNA pools
were arrayed in 96-well plates for the primary
transfection-based screening experiments.
Each pool of cDNAs from the library was co-
transfected into p53-negative H1299 cells together with
p53 and mdm2. The absolute levels and ratios of overex-
pressed p53 and Mdm2 were optimized to allow both in-
creases and decreases in their abundance to be detected.
To monitor Mdm2 activity as well as Mdm2 and p53
abundance in the absence of co-transfected cDNAs from
the library, control transfections using only p53 or p53
and mdm2 were performed. As an additional control to
determine whether cDNA library pools have a general
impact on protein turnover we also transfected the
Wnt-receptor protein ror2 (Fig. 1). Twenty-four hours
post-transfection total cell lysates were prepared and
the amount of p53, Mdm2 and ROR2 proteins was
determined by SDS-PAGE and Western Blotting ana-
lysis (Fig. 1). Each library pool was analyzed at least
twice and only pools that specifically altered the
abundance of co-expressed p53 and/or Mdm2 in at
least two experiments were considered as candidates.
Using this primary screening approach, we identified
one hundred and six pools that either increased or
decreased abundance of p53 or Mdm2 or both (Table 1).
The majority of the hits increased the abundance of either
p53 alone or of p53 and Mdm2, while a lower number of
library pools resulted in decreased p53 and/or Mdm2
abundance.
In order to confirm that the complexity of the primary
screening conditions would not prevent identification of
p53 modulators, we spiked a non-modifying (control)
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pool from the library with plasmid DNA encoding
the known p53 modifiers p14ARF and USP7 (see
Additional file 1). P14ARF stabilizes p53 by prevent-
ing the Ubiquitin-mediated degradation of p53 by
Mdm2 [9] and the ubiquitin-specific protease USP7
deubiquitinates both Mdm2 and p53, resulting in
their stabilization [10]. Co-expression of p14arf and
usp7 in amounts similar to those of the individual
clones present in the screened pools (about 6 ng) resulted
in the expected stabilization of p53 and Mdm2, confirm-
ing the suitability of the primary screening conditions (see
Additional file 1). Indeed, one of the candidate pools iden-
tified in the primary screening contains the Medaka usp7
gene homologue. The Medaka p14arf homologue was
however not present in the library.
In order to identify which genes in the candidate pools
were responsible for regulating p53 and/or Mdm2 abun-
dance, we performed a secondary screen using the
twenty-four single cDNA clones contained within each
candidate pool. The individual cDNA clones were ampli-
fied from the arrayed master library and, like the
primary screen, were transfected together with p53,
mdm2 and ror2 (Fig. 2a). Each cDNA was analyzed at
least twice and only those clones that altered p53 and/or
Mdm2 abundance in at least two experiments were con-
sidered as candidates. From the one hundred and six
pool hits that were identified in the first round of
screening, the secondary screening procedure was per-
formed on twenty. The majority (eleven) of these twenty
pools harbored a single regulator of p53 or p53 and
Mdm2, two pools harbored two regulators and, strik-
ingly, one pool harbored three apparent regulators of
p53 and Mdm2 (Fig. 2, Table 2). Thus, overall, 70 % of
candidate pools identified and selected for secondary
screening were found to contain regulators of p53 and/
or Mdm2. Six of the identified regulators affected only
p53 and two of the cDNAs affected only Mdm2 abun-
dance. Four of the identified novel regulators increased
Mdm2 abundance and decreased p53 abundance and six
increased both p53 and Mdm2 abundance (Table 2).
Among the seventeen cDNAs that we found to regulate
p53 or p53 and Mdm2, twelve were annotated and five
Fig. 1 Screening of a Medaka cDNA library. a Schematic drawing of
the screening process. 24 clones of the cDNA library were pooled
and all pools were arrayed in 96-well plates. P53-negative H1299
cells were transfected in 96 well-plates with p53 (5 ng), mdm2
(45 ng), one of the cDNA library pools (150 ng) and myc-ror2 (5 ng)
as control. To monitor Mdm2 activity, and Mdm2 and p53 abundance
in the absence of co-transfected pools of the cDNA library, 2 out of 14
wells were transfected with p53 and myc-ror2 (control 2) or with p53
and mdm2 and myc-ror2 (control 1) without library pools. For
transfection, total amounts of plasmid DNA in all samples were
adjusted to 205 ng using vector DNA. 24 h after transfection,
cells were lysed and abundance of p53, Mdm2 and Myc-ROR2
were determined by Western Blotting. Abundance of PCNA was
monitored for loading control. b H1299 cells were transfected
with plasmids encoding p53, Mdm2 and Myc-ROR2 together
with the indicated pools of the cDNA library, without the library
(ctrl 1) or without the library and without the plasmid encoding
Mdm2 (ctrl 2), for control. 24 h after transfection, cells were
lysed and abundance of p53, Mdm2, Myc-ROR2 and PCNA
were determined by Western Blotting
Table 1 Summary of the screening of a Medaka cDNA library
for evolutionarily conserved regulators of p53 and Mdm2. The
table shows the number of hits and their activity on the
abundance of p53and/or Mdm2
Property Number of hits
p53 abundance is decreased 6
p53 abundance is increased 38
Mdm2 abundance is decreased 3
Mdm2 abundance is increased 11
p53 and Mdm2 abundance is decreased 1
p53 and Mdm2abundance is increased 43
p53 abundance is increased, Mdm2
abundance is decreased
1
p53 abundance is decreased, Mdm2
abundance is increased
3
Total 106
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had unknown sequences. The molecular function of the
genes that we found in the sub-screen (Table 2) ranged
from a putative MAPK-activating protein (C1ORF144/
SZRD11, [11]) to a lysosomal protein that is involved in the
catabolism of heparin and keratan sulphate (GNS; [12]).
Several of the cDNAs identified in the secondary
screen were again transfected into H1299 cells to con-
firm that they indeed regulate the levels of p53 and/or
Mdm2. All of the identified Medaka clones regulated
p53 and/or Mdm2 (Fig. 3), confirming the result from
the secondary screen.
We have performed a cell culture-based cross-species
expression screen where a cDNA library from Medaka
was used to screen for regulators of human p53 and
mouse Mdm2 in human cells. One aim of this screen
was to identify evolutionarily conserved modifiers of the
p53 signaling pathway. Considering the evolutionary dis-
tance of teleosts and mammals we tested whether the
human orthologues of the identified Medaka genes
would also be able to regulate p53 and Mdm2. As shown
in Fig. 4, the human orthologues of some of the genes
identified (e.g. c1orf144, trim25, fam83f and rbm15) also
regulated p53 and/or Mdm2 abundance (Fig. 4).
C1ORF144/SZRD1, increased p53 abundance, TRIM25
increased p53 and Mdm2 abundance, FAM83F increased
p53 abundance and decreased Mdm2 abundance and
RBM15 increased Mdm2 abundance and decreased p53
abundance. We also tested the ability of C1ORF144/
SZRD1 and FAM83F to regulate endogenous p53 levels
in p53-positive cells and in each case we could see the
Fig. 2 Subscreening of the Medaka cDNA library. a From the cDNA pools that were considered to contain regulators of p53 and/or Mdm2, the
individual bacteria were amplified from the master library. The plasmids were purified and 12.5 ng of the individual cDNAs were transfected
together with p53 (5 ng), mdm2 (45 ng) and myc-ror2 (5 ng) into H1299 cells in a 96-well format. 24 h after transfection, cells were analyzed by
Western Blotting. b H1299 cells were transfected with plasmids encoding p53, Mdm2 and Myc-ROR2 together with the individual clones of the
indicated pool hit or with plasmids encoding p53, Mdm2 and Myc-ROR2 without cDNA clones, for control (ctrl). 24 h after transfection, cells were
harvested and analyzed as described in the legend to Fig. 1
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expected effect (see Additional file 2). Furthermore, we
recently demonstrated that TRIM25 also regulates en-
dogenous p53 [13]. These results demonstrate that cell
culture-based expression screening using a cDNA library
from Medaka can identify evolutionarily conserved regu-
lators of p53 and Mdm2.
Discussion
We have performed a cross-species cell-based overex-
pression screen using a Medaka cDNA library to screen
for novel regulators of p53 and Mdm2 in human cells.
SDS-PAGE and Western blotting was used as a read–out
to specifically detect the abundance of these proteins.
Since the cDNA library contained more than seventeen-
thousand genes, we used pools of twenty-four individual
cDNAs for transfection. Strikingly, we found more than
one hundred cDNA pools that altered the abundance of
co-transfected p53 and Mdm2 in p53-negative H1299
cells. The strategy of using pooled cDNAs in the primary
screen, where only six nanograms of each individual clone
was co-expressed with p53 and mdm2, likely resulted in
missed hits (i.e. false negatives), due to limits in sensitivity.
About two hundred nanograms is the maximum amount
of plasmid DNA that can be transfected in 96-wells with-
out significantly increasing cell toxicity and for this reason
it was considered counter productive to further increase
the amount of library clones in the primary screen. In the
secondary screens, where double the amount of individual
cDNA clones were transfected compared to the primary
screen, a more robust modification of p53 and/or Mdm2
protein levels were indeed seen. Reducing the pool size to
twelve rather than twenty-four would likely result in the
identification of additional modifiers, however every
screening experiment has its particular limitations and we
believe that a good compromise was achieved using our
strategy. Another reason for missing potential regulators
is that the activity of one regulator can be masked by an
opposing activity of additional regulators present in the
same pool. Although this is unlikely to be a major factor,
the surprising identification of three independent
Table 2 Regulators of p53 and Mdm2 identified by subscreening of the Medaka cDNA library. The table shows the number of the
clone in the library, the identification number of the Ensembl database (Ensmble ID), the name of the gene, further details about
the protein and its activity within the p53/Mdm2 circuit
Clone number Ensembl ID Gene name Activity towards p53 and Mdm2
2.2 B6 not annotated unknown p53 abundance was increased
5.3D G3 ENSORLG00000007935 q3v605_oryla Hoxc8a protein p53 abundance was increased
5.3D G10 ENSORLG00000008784 galntl1 UDP-N-acetyl-alpha-D-galactosamine:
polypeptide N-acetylgalactosa-
minyltransferase-like 1
p53 and Mdm2 abundance were
increased,
6.3 H5 ENSORLG00000003540 fubp1 far upstream element-binding protein 1 p53 abundance was decreased, Mdm2
abundance was increased
8.3D G10 ENSORLG00000006197 rbm15 RNA binding motif protein 15 p53 abundance was decreased, Mdm2
abundance was increased
9.1 H11 ENSORLG00000001826 trim25 Tripartite motif-containing protein 25 p53 and Mdm2 abundance were
increased
10.4 B10 ENSORLG00000009742 bhlhe23 Basic helix-loop-helix family member e23 p53 abundance was increased
10.4 B12 ENSORLG00000009430 srsf4 Serine/arginine-rich splicing factor 4 p53 abundance was increased
15.1 F10 FOE002-P00040-DPE-F_A21 unknown p53 abundance was decreased, Mdm2
abundance was increased
15.2C F9 not annotated unknown p53 abundance was decreased, Mdm2
abundance was increased
15.3 G5 ENSORLG00000016835 gns Glucosamine (N-acetyl)-6-sulfatase p53 and Mdm2 abundance were
increased
15.4 C4 ENSORLG00000004985 mex3c Mex-3 homolog C p53 abundance was increased
18.2 F5 ENSORLG00000000208 c1orf144 C1-open reading frame 144 (PM20, PM21) p53 abundance was increased
29.3 F1 ENSORLG00000004520 hsd1 1b 1 l Hydroxysteroid (1 l-beta) dehydrogenase
1-like
p53 and Mdm2 abundance were
increased
36.4 B D5 not annotated unknown p53 and Mdm2 abundance were
increased
36.4 B D6 not annotated unknown Mdm2 abundance was increased
45.1 B2 ENSORLG00000001401 fam83f Family with sequence similarity 83,
member F
p53 abundance was increased
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Fig. 3 cDNAs identified in a screen using a cDNA library from Medaka induced mammalian p53 and Mdm2. H1299 cells were transfected with
the indicated cDNAs together with plasmids encoding p53, Mdm2 and Myc-ROR2. For control, cells were transfected only with plasmids encoding
p53, Mdm2 and Myc-ROR2. 24 h after transfection, cells were harvested and analyzed as described in the legend to Fig. 1
Fig. 4 Human homologs of the cDNAs that were identified by screening a Medaka cDNA library control p53 and Mdm2 abundance. H1299 cells
were transfected with increasing amounts of plasmids encoding human Myc-tagged C1ORF144, human V5-tagged TRIM25, human Flag-tagged
FAM83F and human Flag-tagged RBM15 together with plasmids encoding p53 and Mdm2. For control, cells were transfected only with plasmids
encoding p53 and Mdm2. 24 h after transfection, cells were harvested and analyzed as described in the legend to Fig. 1
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regulators in one of the pools confirms that this is an issue
worth considering. In spite of these limitations, more than
one hundred hits were identified using the library pools,
several of which have indeed been verified.
Twenty of the pools identified in the first round of
screening were selected for a second round of screening
in order to isolate the corresponding p53/Mdm2 modi-
fier. Fourteen of the twenty pools indeed contained at
least one cDNA that regulated p53, which represents a
success rate of 70 %. One of the clones that we identified
as a regulator of p53 and/or Mdm2, the splicing factor
FUBP1 (far upstream binding protein 1) is already
known to stabilize p53 in response to oxidative stress
[14] yet all other regulators of p53 identified in the sub-
screen were not previously known to regulate p53 or
Mdm2. Due to the relatively well annotated nature of
the cDNA library it is possible to scan the library
database for the identity of putative regulators within a
candidate pool. One of the pools identified in the pri-
mary screen was found to harbor the known p53 and
Mdm2 regulatory gene, usp7 [10]. Other known regula-
tors of p53 or Mdm2 like p14Arf do not appear to be
present in the library. Nevertheless, as discussed above,
it is not possible to find all regulators of p53 and many
of the pools identified in the primary screening have yet
to be analyzed by secondary screening. Indeed, we only
subscreened 20 % of the library. Thus, it is possible that
the remaining 80 % of the library will also contain some
known regulators of p53 and/or Mdm2 that were not
annotated. Finally, this library was prepared from mRNA
extracted from developing embryos and early juvenile
fish and it is unlikely that all regulators of p53 will be
represented.
Our previous success in searching for evolutionarily
conserved interactors using cross-species screening
methods [15, 16] prompted us to use a full length uni-
gene library from the teleost Medaka to screen for evo-
lutionarily conserved regulators of mammalian p53 and
Mdm2. Several of the hits were validated after subse-
quent analysis of the corresponding human orthologues.
Importantly, all human homologs analyzed regulated
p53 and Mdm2 in the same way as the Medaka library
genes. Thus, although Medaka and humans are evolu-
tionarily highly divergent, the principle mechanism used
to regulate p53 levels appears to be highly conserved.
The use of a Medaka cDNA library to screen for reg-
ulators of human genes is a promising approach in
other areas of research. The main challenge will be to
characterize the mode of action of the identified
regulators.
Conclusions
Our results show that it is possible to identify regulators
of p53 and Mdm2 levels by performing a cross-species,
cell-based cDNA library expression screen. Rapid screen-
ing of the entire library of over seventeen thousand genes
was made possible by preparing pools of library cDNAs
that were used in the primary screening method. It is
likely that such a screening method can also identify regu-
lators of the abundance of other cellular proteins.
Methods
Cell lines and their treatments
H1299 cells (p53-negative) were cultured in DMEM
containing 10 % foetal bovine serum (FBS) and 1 % peni-
cillin/streptomycin according to standard conditions.
For transfection of the library, 5x104 cells/well were
transferred into 96-well plates and transiently trans-
fected with 150 ng DNA from the cDNA library, 5 ng
p53, 45 ng mdm2 and 5.5 ng 6xmyc-ror2 using Promo-
Fectin (PromoKine) according to the manufacturer’s rec-
ommendation. The total amount of transfected cDNA
was always kept constant at 205.5 ng for all samples, in-
cluding controls, and adjusted with empty vector DNA
where necessary.
Medaka cDNA library
The library has been described in [8]. Small aliquots
from the individual bacterial clones of the arrayed Me-
daka library (in 384 well plates) were first transferred to
184 x 96-well plates containing 180 μl LB broth + 10 %
glycerol and amplified for 24 h at 37 °C using a high fre-
quency orbital shaker. A total of 17.525 individual clones
were amplified in this way, creating a duplicated bacter-
ial library in 96-well format. Bacterial cultures from two
adjacent rows of the 96-well plates (24 individual wells)
were then pooled (4 ml volume) and used for mini-prep
isolation of plasmid DNA (Qiagen kit). A total of 732
pooled plasmid DNA samples were then arrayed in 96-well
PCR plates as transfection ready cDNA library pools.
150 ng of these pools were used for the primary
transfection-based screening experiments.
Plasmids
The plasmids encoding p53 and mdm2 have been
described earlier [7]. Myc-ror2 was constructed by PCR
amplification. First, 6myc-tags were amplified and
inserted into pCS2+ at EcoR1 and Sac1 sites, followed by
insertion of PCR-amplified ror2 into Sac1 and XbaI sites.
v5-tagged trim25 was amplified by PCR with inclusion
of the sequence for the V5-tag in the forward primer
using a plasmid for human gfp-trim25 that has been sent
to us by Germana Meroni. myc-tagged c1orf144 was
amplified by PCR with inclusion of the sequence for the
Myc-tag in the forward primer and reversely transcribed
RNA as a template. flag-tagged fam83f was amplified by
PCR with inclusion of the sequence for the Flag-tag in
the forward primer and reversely transcribed RNA as a
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template. Sequences of cloning primers are available on
request. flag-tagged rbm15s was provided by Stephen
Morris, p14ARF by Karen Vousden and usp7 by Wei Gu.
The plasmids encoding mdc1orf144, mdmex3c, mdtrim25,
mdbhlhe23, mdsrsf4, mdhsd11b1l, mdfam83f mdgns, clone
2.2 B6, clone 34.4 B D6, clone 36.4B D5, clone 36.4 B D8,
mdQ3V605_Oryla, mdgalntl1, mdfubp1, clone 15.1 F10,
clone 15.2 C F9 and mdrbm15 have been obtained directly
from the Medaka library.
Antibodies
The antibodies DO-1 (p53), PC10 (anti-proliferating
nuclear cell antigen; PCNA) and 9E10 (Myc) were
purchased from Santa Cruz. The anti-V5 antibody was
obtained from Serotec and the anti-Flag antibody was
from Sigma. HRP-coupled secondary antibodies were
purchased from Dako.
SDS-PAGE and Western blotting
Cells were washed with PBS and lysed in NP40 lysis buf-
fer (50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA,
1 % NP40, 1 mM PMSF) for 10 min on ice. Lysates were
centrifuged at 20.000 g for 2 min to remove insoluble
material and clarified supernatants were mixed with an
equal volume of 2x sample buffer (4 % sodiumdodecyl-
sulfate (SDS), 160 mM Tris pH6.8, 20 % glycerol, 10 %
2-mercaptoethanol, 0.002 % bromophenol blue). The
samples were heated at 95 °C for 4 min, loaded onto an
SDS-10 % polyacrylamide gel, separated by electrophoresis
and transferred onto a polyvinylidene difluoride (PVDF)
membrane (Millipore). Membranes were blocked for
30 min in 5 % dry milk and 0.2 % Tween-20 in PBS and
incubated overnight with the primary antibodies. After
washing 3 times for 5 min in 0.2 % Tween-20 in PBS, the
secondary antibody was added and incubated for 1.5 h.
After extensive washing, the blots were developed by
adding ECL and exposing the membranes against an
X-ray film.
Availability of supporting data
All supporting data are included as supplementary files.
Additional files
Additional file 1: Effect of known modifiers of p53 using the
primary screening conditions with cDNA pools. Western Blot of
lysates from H1299 cells transfected as indicated in 96-well format and
harvested 30 h post-transfection. In order to create the complexity of the
primary screening conditions, 100 ng of a control (non-modifying) cDNA
library pool was spiked with 5 ng and 10 ng of genes encoding the
known p53 modifiers hP14ARF and hUSP7, and co-transfected with of
p53 (5 ng) and mdm2 (50 ng) (lanes 3–7). As controls a non-functional
USP7 mutant was used, as well as a candidate cDNA library pool containing
the C1orf144 gene encoding szrd1, which wasidentified as a positive hit for
p53 stabilisation, (lane 2). (PDF 868 kb)
Additional file 2: Regulation of endogenous p53 and its target
gene Bax after overexpression of c1orf144 or Fam83F. A. U2OS cells
were transfected with a plasmid encoding human C1ORF144 or with
vector DNA for control using Promofectin. B. MCF-7 cells were transfected
with a plasmid encoding human FAM83F or with vector DNA for control
using Promofectin. All transfections were performed with 2 μg of plasmid
DNA in 24-well plates. The cells were lysed 24 h after transfection. Abundance
of p53 and Bax was monitored by Western blotting. (PDF 325 kb)
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